Product
Galcanezumab
Aliases
Emgality®, LY2951742
Name
EMGALITY
INN Name
galcanezumab-gnlm
FDA Approved
Yes
8 clinical trials
1 organization
3 indications
1 document
Indication
MigraineIndication
Trigeminal NeuralgiaIndication
Glossopharyngeal NeuralgiaClinical trial
Autonomic Functions in Migraine Patients as a Function of Migraine Status and CGRP InhibitionStatus: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 StudyStatus: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 StudyStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic MigraineStatus: Completed, Estimated PCD: 2023-05-23
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist StudyStatus: Completed, Estimated PCD: 2021-07-27
Clinical trial
An Exploratory, Prospective, Randomized, Pragmatic Open Label Cohort Study to Evaluate the Comparative Effectiveness of Eptinezumab in the United StatesStatus: Terminated, Estimated PCD: 2023-02-17
Clinical trial
Prospective Evaluation of Emgality (Galcanezumab) in Breastmilk in Adult Women With MigraineStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/FibromyalgiaStatus: Completed, Estimated PCD: 2023-01-04
Document
DailyMed Label: EMGALITYOrganization
Eli Lilly and Company